99
Participants
Start Date
September 30, 2003
Primary Completion Date
January 31, 2004
Study Completion Date
January 31, 2004
Placebo 0.04 mL twice daily
Subcutaneously injected, 0.04 mL, twice daily
Placebo 0.04 mL once daily
Subcutaneously injected, 0.04 mL, once daily
Placebo 0.08 mL once daily
Subcutaneously injected, 0.08 mL, once daily
B - Exenatide 10 mcg twice daily
Subcutaneously injected, 10 mcg (0.04 mL), twice daily
C - Exenatide 10 mcg once daily
Subcutaneously injected, 10 mcg (0.04 mL), once daily
Exenatide 20 mcg once daily
Subcutaneously injected, 20 mcg (0.08 mL), once daily
Rochester Clinical Research, Inc., Rochester
Philadelphia Health Associates - Adult Medicine, Philadelphia
MedStar Research Institute, Washington D.C.
McGuire VA Medical Center, Richmond
Piedmont Medical Research Associates, Winston-Salem
Metrolina Medical Research, Charlotte
Jacksonville Center for Clinical Research, Jacksonville
Innovative Research of West Florida, Largo
Internal Medicine Associates, Department of Research, Fort Myers
Radiant Research, Columbus
Smith Clinic Research, Marion
Henry Ford Health System, Detroit
Grand Rapids Associated Internists, Grand Rapids
Mercury Street Medical Group, Butte
Internal Medicine Associates, Bozeman
Radiant Research, Inc., St Louis
S.A.M. Clinical Research Center, San Antonio
Lovelace Scientific Resources, Las Vegas
The Whittier Institute for Diabetes, La Jolla
VA Medical Center, San Diego
Radiant Research, Portland
Rockwood Clinic, Spokane
Diabetes and Glandular Disease Research Associates, San Antonio
Lead Sponsor
Eli Lilly and Company
INDUSTRY
AstraZeneca
INDUSTRY